SGLI2i and dulaglutide similar in reducing dementia risk
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.09.06 05:31:29
가나다라
0
Sungkyunkwan University Professor Ju-young Shin’s research team conducted research comparing SGLT2 inhibitor and dulaglutide
Demonstrated that there was no significant difference in dementia risk between the 2 treatments in a study comparing their effect in preventing the development of dementia
Paper published in Annals of Internal Medicine, one of the world's leading medical journals
With interest in the dementia prevention effect of Type 2 diabetes medications such as SGLT-2 inhibitors and GLP-1 RAs rising, a study has been published in Korea on the relative prevention effect between the two medications.
▲(from the left) Professor Ju-young Shin, Ph.D candidate Bin Hong, Dr. Sungho Bea, Ph.D candidate Hwa Yeon Ko
On the 3rd, Sungkyunkwan University College of Pharmacy Professor Ju-young Shin’s research team (First author: Bin Hong, coauthor Sungho Bea) announced today that it had published results of a research comparing the dementia prevention effects of SGLT2 inhibitors and dulaglutide in patients with type 2 diabetes using Korea’s healthcare big data.
Dementia is a debilitating neurodegenerative disease characterized by cognitive decline and memory loss. Type 2
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)